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Abstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured 
by Merck Pharmaceuticals, has received US Food and Drug Administration approval for 
treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin 
or metformin alone or together in free-dose combination form. Sitagliptin, an inhibitor of the 
enzyme DDP-4, assists patients with type 2 diabetes mellitus to achieve glycemic control. It has 
been shown to be safe and effective at 100 mg daily doses. The effect of giving sitagliptin in 
combination with metformin is thought to have a complimentary and possibly additive effect 
on glycemic control.
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Introduction
In 2007 it was estimated that 17.9 million Americans were diagnosed with type 2 
diabetes mellitus (T2DM). Additionally it was estimated that 5.7 million people 
had T2DM but were undiagnosed at the time. Together these numbers suggest that 
23.6 million people or 7.8% of the population of the United States that have T2DM. 
In 2007 in the USA an estimated 1.6 million people were diagnosed with T2DM and 
that 57 million Americans over the age of 20 years have impaired fasting glucose or 
prediabetes.1
There is strong evidence demonstrating that benefits can be achieved from tight 
glycemic control.2–5 Many patients with T2DM remain uncontrolled despite a wide 
range of treatment options available to treat patients with T2DM including metformin, 
sulfonylureas, meglitinides, α-glucosidase inhibitors, thiazolidinediones, and insulin.6 
It was found that the average glycosylated hemoglobin (A1C) of patients with a 
diagnosis of DM increased from 7.7% to 7.9% between 1990 and 1999.2 Considering 
the large number of people who currently have or will have T2DM and the difficulties 
providers face in establishing glycemic control it becomes clear that there is a need 
for new agents with novel mechanisms of action to increase the number of options 
available to both patients and healthcare providers.
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new therapeutic target for 
the treatment of T2DM. The first DPP-4 inhibitor to be approved by the US Food and 
Drug Administration (FDA) was sitagliptin (JanuviaTM) in October 2006. Sitagliptin 
is approved for use as monotherapy or as add-on therapy to ongoing metformin, 
thiazolidinedione, sulfonylurea (±metformin.) A fixed-dose combination tablet Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 128
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containing both sitagliptin and metformin (JanumetTM) was 
approved by the FDA in April 2007 and is marketed by 
Merck Pharmaceuticals. This fixed-dose combination tablet 
is available to provide patients requiring both sitagliptin and 
metformin to meet their A1C goals. The other DPP-4 inhibitor 
that is currently in use is vildagliptin which is available in 
the EU but not in the USA.
Mechanism of action
Sitagliptin
Insulin is secreted in response to elevation of plasma glucose. 
But it has been found that oral glucose intake augments 
insulin secretion three- to four-fold more as compared to an 
intravenous infusion of glucose that results in an identical 
elevation of plasma glucose.7 This augmentation of insulin 
secretion following the intake of oral glucose is known 
as the incretin effect. The effect is due to the release of 
incretins which are gut-derived hormones that are capable 
of potentiating the release of glucose dependent insulin 
secretion from the pancreas.7 Incretins are released into 
circulation after ingestion of food. Once in circulation they 
stimulate insulin release from the pancreas in a glucose-
dependent manner.8
GLP-1 which is released from the endocrine L cells of the 
small intestine and GIP which is released from the K cells7,9 
are two of the incretin hormones that increase insulin 
secretion in the presence of elevated glucose concentrations. 
The incretin effect of GLP-1 and GIP is additive and together 
they are responsible for the majority of the incretin action 
which accounts for approximately 60% of the postprandial 
insulin response.7 In addition to directly increasing insulin 
secretion in a glucose-dependent manner, incretins exert 
other effects that help contribute to glycemic control. These 
other effects include; inhibiting appetite,10 lowering glucagon 
secretion,11 decreasing gastrointestinal motility, and delaying 
gastric emptying.12,13
It has been found that lower concentrations of active 
GLP-1 is associated with an inadequate insulin response.14 
And patients with T2DM have almost no, or a greatly reduced 
incretin effect.7
The GLP-1 and GIP that are released from the L and 
K cells respectively are rapidly degraded and inactivated 
through metabolism mediated by the DPP-4 enzyme.11 
It is estimated that upwards of 75% of the GLP-1 is 
inactivated before leaving the intestines and 40%–50% of 
the remaining GLP-1 is then degraded in the liver. This 
leaves only about 10%–15% of GLP-1 to enter systemic 
circulation.15
DPP-4 is a serine protease located on the surface 
of cells in the kidneys, intestines, bone marrow, liver, 
pancreas, placenta, thymus, spleen, epithelial cells, 
vascular endothelium, and lymphoid and myeloid cells.14 
DDP-4 inhibitors such as sitagliptin block the enzymatic 
inactivation of the incretins which results in higher levels 
of active incretins in circulation. The release of incretins is 
dependent upon the presence of nutrients in the gut. Since 
the insulin-releasing effects of the incretins are glucose-
dependent, insulin levels are only increased in response to the 
body’s need for insulin which decreases the patient’s risk of 
hypoglycemia while still improving glycemic control.11
Metformin
While the mechanisms of action through which metformin 
exerts its various effects remains somewhat unclear, it is 
clear that metformin contributes to glycemic control in a 
variety of ways. In a review of the available research in 1999, 
Wiernsperger and Bailey reported that metformin assists in 
glycemic control in many ways including reducing hepatic 
glucose output, increasing peripheral glucose utilization, 
decreasing fatty acid oxidation, reducing appetite and weight 
gain, and sensitizing peripheral tissue to insulin action, 
increasing the functional activity of glucose transporters, and 
increasing insulin-mediated insulin receptor tyrosine kinase 
activity, which then augments a range of insulin signals.16
The precise mechanisms of action by which metformin 
lowers the basal and postprandial blood glucose in T2DM 
are not completely understood. But, it is thought that at 
least some of the therapeutic effects of metformin are 
mediated through GLP-1.17 Metformin significantly increases 
GLP-1 levels after an oral glucose load in obese nondiabetic 
patients.18 And it has been suggested that metformin does 
not directly inhibit DPP-4 but rather it enhances GLP-1 
secretion.17 Since metformin appears to increase levels of 
GLP-1 in a different way than the DPP-4 inhibitors the 
combined effect of combination therapy with metformin and 
sitagliptin is thought to be complimentary.
Efficacy
When given as monotherapy19–23 and in combination with 
metformin,24–28 sitagliptin has been shown to be generally 
well tolerated and to improve A1C and other indices of 
glycemic control relative to placebo in patients with T2DM. 
200 mg once daily doses of sitagliptin did not show an 
efficacy advantage over sitagliptin 100 mg once daily.20,21 
Sitagliptin monotherapy administered in 50 mg twice daily 
doses was found to be more effective than lower twice Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 129
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daily doses.19 The glycemic response between sitagliptin 
100 mg once daily did not differ from that of sitagliptin 
50 mg twice daily.23
The fixed-dose combination tablet of sitagliptin/
metformin is designed to be dosed twice daily and is available 
in two tablet strengths; sitagliptin 50 mg/metformin 500 mg 
and sitagliptin 50 mg/metformin 1000 mg.
A study conducted by Goldstein and colleagues28 
demonstrated the additive effect on glycemic control of 
combination therapy with sitagliptin and metformin. This 
was a randomized, placebo-controlled, parallel-group, 
double-blind study of 1,091 patients with T2DM who were 
inadequately controlled on diet and exercise alone (A1C 
of 7.5%–11%) that was conducted over a 24-week period. 
Subjects were randomized to one of six arms to receive 
placebo, metformin monotherapy, sitagliptin monotherapy, 
or sitagliptin/metformin combination therapy.28 Relative to 
placebo, all active treatments showed significant reductions 
in A1C (P  0.001) at week 24 as compared to baseline 
(Table 1). It was found that sitagliptin monotherapy (n = 175) 
lowered A1C by approximately 0.66% as compared to base-
line and that metformin monotherapy (n = 177) lowered A1C 
by approximately 1.13%. It was also found that the sitagliptin 
50 mg/metformin 1,000 mg combination (n = 178) lowered 
A1C by approximately 1.9% as compared to baseline. The 
magnitude of the placebo-adjusted reduction in A1C in the 
combination therapy groups as compared to the monotherapy 
groups demonstrates that there is an additive response when 
sitagliptin and metformin are given together.28
Several other trials have been conducted that added 
sitagliptin to patients with T2DM who were currently under 
poor control with metformin or other therapy for glycemic 
control21,22,24–27,29 (Table 2). FDA approval of fixed-dose 
metformin/sitagliptin (JanumetTM) was based on the study by 
Charbonnel and colleagues that concluded that the addition 
of sitagliptin 100 mg dosed once daily to ongoing metformin 
therapy was efficacious and well tolerated in patients with 
T2DM who were inadequately controlled on metformin 
therapy alone.25
Kinetics
The oral bioavailability of sitagliptin is 87%. Administering 
sitagliptin with food does not alter the Tmax or the half life. The 
volume of distribution is 198 L and it is approximately 38% 
bound to plasma proteins.30 Sitagliptin is a minor substrate 
for CYP 3A4 and 2C837 but it is neither an inhibitor nor an 
inducer of the P450 system30 and moderate hepatic impairment 
does not appear to significantly alter the pharmacokinetic 
profile of sitagliptin.31 The primary elimination route of 
sitagliptin is via active tubular secretion in the kidneys 
(∼79%) and the terminal half-life is 8–12 hours. Dosage 
adjustments are recommended in moderate to severe renal 
impairment.32 There appears to be no clinically important 
pharmacokinetic interactions requiring dosage adjustment 
with agents co-administered with sitagliptin.33
Safety
Sitagliptin
In 2007, Amori and colleagues conducted a systematic review 
on the efficacy and safety of incretin therapy. The incretin 
therapy they studied included two incretin memetics or GLP-1 
analogues; exenatode, liraglutide and two DPP-4 inhibitors; 
sitagliptin and vildagliptin. The findings for the two DPP-4 
inhibitors were reported together in the review.34
Both of the DPP-4 inhibitors were found to lower A1C 
similarly compared with placebo (-0.74% for sitagliptin 
and -0.73% for vildagliptin). The DPP-4 inhibitors were 
slightly less effective compared with other hypoglycemic 
agents (weighted mean difference, 0.21%; 95% confidence 
interval [CI]: 0.02%–0.39%).34
Table 1 Glycosylated hemoglobin (A1C) endpoints for the treatment arms studied by Goldstein and colleagues28
Treatment arm n A1C at baseline A1C at week 24 Change in A1C (%) from 
baseline to week 24
Metformin/sitagliptin 
1,000 mg/50 mg bid
178 8.76% ± 0.95% 6.87% ± 1.09% -1.90% (-2.06% to -1.74%)
Metformin/sitagliptin 
500 mg/50 mg bid
183 8.79% ± 1% 7.37% ± 1.20% -1.40% (-1.56% to -1.24%)
Metformin 1,000 mg bid 177 8.68% ± 0.91% 7.58% ± 1.27% -1.13% (-1.29% to –0.97%)
Metformin 500 mg bid 178 8.90% ± 1% 8.04% ± 1.36% -0.82% (-0.98% to -0.66%)
Sitagliptin 100 mg qd 175 8.87% ± 0.99% 8.18% ± 1.45% -0.66% (-0.83 to -0.50%)
Placebo 165 8.68% ± 1% 8.88% ± 1.47% 0.17% (±0.00–0.33)Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 130
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DPP-4 inhibitors were found to be more likely to 
lower A1C below 7% compared to placebo (43% vs 17%, 
respectively; risk ratio [RR], 2.5%; 95% CI: 2.1–2.8) with 
no difference between the two DPP-4 inhibitors.34
The DPP-4 inhibitors reduced fasting plasma glucose 
more than placebo and sitagliptin was favored over 
vildagliptin in this category.34
Weight was increased slightly with DPP-4 inhibitors as 
compared to placebo (weighted mean difference, 0.5 kg; 
95% CI: 0.3–0.7 kg) noninferiority trials revealed the weight 
profile favored sitagliptin over glipizides (-2.5 kg vs 1.0 kg, 
respectively).34
The review found that none of the trials revealed any 
consistent changes in lipid profile with either DPP-4 
inhibitor as compared with placebo but there were some 
improvements in triglycerides and low- and high-density 
lipoprotein cholesterol.34
The incidence of mild to moderate hypoglycemia was found 
to be the same between the DPP-4 inhibitors and comparator 
groups (1.6% vs 1.4%, respectively; RR, 1.0; 95% CI: 0.5–1.9) 
while severe hypoglycemia was only reported in two patients 
taking DPP-4 inhibitors.
The review found the DPP-4 inhibitors exhibited low 
absolute rates of adverse effects. The risk of nasopharyngitis 
(6.4% for DPP-4 inhibitor vs 6.1% for comparator; RR, 1.2, 
95% CI: 1.0–1.4), urinary tract infection (3.2% for DPP-4 
inhibitor vs 2.4% for comparator; RR, 1.5; 95% CI: 1.0–2.2), 
and headache (5.1% for DPP-4 inhibitor vs 3.9% for 
comparator; RR, 1.4; 95% CI: 1.1–1.7) was increased with 
DPP-4 therapy vs comparators.34
In 2009 the Cochrane Collaboration published a review 
of the research conducted on the DPP-4 inhibitors, sitagliptin 
and vildagliptin.35 The research was designed to assess 
the effects of DPP-4 inhibitors for T2DM. The review 
Table 2 Key features and conclusions of trials that added sitagliptin to patients with type 2 diabetes mellitus (T2DM) who were currently 
under poor control with metformin or other therapy for glycemic control
Study authors Treatment arms N Conclusions
Hermansen et al27 Placebo + glimepiride Placebo + 
glimepiride + metformin 
Sitagliptin + glimepiride  
Sitagliptin + glimepiride + 
metformin
Completed N = 87 Completed 
N = 92 Completed N = 83 
Completed N = 102
The addition of sitagliptin 100 mg qd significantly 
improved glycemic control in patients who were 
inadequately controlled with glimepiride or 
glimepiride + metformin
Nauck et al24 Sitagliptin + metformin 
Glipizide + metformin
Completed N = 386 
Completed N = 412
The addition of sitagliptin compared 
with glipizide provided similar A1C lowering 
efficacy over 52 weeks in patients on 
ongoing metformin therapy
Charbonnel et al25 Sitagliptin + metformin  
Placebo + metformin
N = 464 N = 237 Sitagliptin 100 mg qd added to ongoing metformin 
therapy was efficacious and well tolerated in 
patients with T2DM who were inadequately 
controlled on metformin alone
Brazg et al26 Placebo/sitagliptin 50 mg bid + 
metformin Sitagliptin 50 mg 
bid/placebo + metformin
N = 13 N = 15 Addition of sitagliptin 50 mg b.i.d. to ongoing 
metformin therapy was well tolerated and 
improved glycemic control and β-cell function
Raz et al30 Placebo Sitagliptin 100 mg qd 
Sitagliptin 200 mg qd
N = 110 N = 205 N = 206 Sitagliptin was well tolerated and significantly 
improved glycemic control in patients with T2DM 
who were inadequately controlled on exercise 
and diet. Sitagliptin 100 mg qd had a slight 
numerical benefit over sitagliptin 200 mg qd
Scott et al29 Placebo + metformin Sitagliptin 
100 mg qd + metformin 
Rosiglitazone 8 mg qd + 
metformin
N = 92 N = 94 N = 87 Addition of sitagliptin was effective  
and well tolerated in T2DM patients who were 
inadequately controlled on metformin therapy 
alone. Treatment with sitagliptin and rosiglitazone 
produced similar reductions in A1C
Aschner et al21 Placebo Sitagliptin 100 mg qd. 
Sitagliptin 200 mg qd
N = 253 N = 238 N = 250 Once daily sitagliptin monotherapy was well 
tolerated improved glycemic control in the 
fasting and postprandial states and improved 
measures of β-cell function. Sitagliptin 200 mg qd 
was slightly favored over sitagliptin 100 mg qd
Abbreviations: bid, twice daily; qd, once daily.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 131
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included 11 trials of good quality that evaluated sitagliptin 
therapy with a total of 6,743 patients. Six trials in the review 
compared sitagliptin monotherapy with placebo.19–23,28 
Two trials compared sitagliptin use with other single agent 
hypoglycemic treatment.19,28 And six of the trials compared 
sitagliptin combination therapies with other combination 
therapies of hypoglycemic agents.19,24,25,27,28,36 Most of the 
studies lasted 24 weeks.35
The Cochrane review concluded that sitagliptin was overall 
well tolerated. The review found that all-cause infections 
showed a statistically significant increase after sitagliptin 
treatment (RR 1.15, 95% CI: 1.02–1.31; P = 0.003).35
Severe hypoglycemia was not reported in patients taking 
sitagliptin. Headache was reported more often with DPP-4 
inhibitors. Sitagliptin therapy did not result in weight gain 
but weight loss was found to be more pronounced following 
placebo therapy.35
None of the trials that were reviewed published data on 
mortality, cost of care, diabetic complications, or health-
related quality of life.35
There are no clinically significant drug interactions 
with sitagliptin. Sitagliptin 200 mg given once daily for 
five days to 12 patients (nine men and three women) did 
not alter the pharmacokinetics of simvastatin given as one 
20 mg dose on day 5 of sitagliptin therapy.37 Likewise 
the pharmacokinetics of rosiglitazone were not altered by 
coadministration of a daily dose of 200 mg of sitagliptin in 
12 patients (eight men and four women).38 Coadministra-
tion of 100 mg of sitagliptin daily with one dose of 600 mg 
of cyclosporine caused the t½ of sitagliptin to fall from 
11.6 hours to 10.6 hours (P = 0.016), increased the Cmax of 
sitagliptin from 706 nmol/L to 1185 nmol/L and increased the 
renal clearance of sitagliptin from 92 ml/min to 121 ml/min.39 
0.25 mg of digoxin co-adminstered daily with 100–200 mg 
of sitagliptin for at least 10 days resulted in an increase in 
the area under curve (AUC) of digoxin of 11% and 18%, 
respectively, and a small increase in the fraction of digoxin 
excreted in the urine was observed.40
Metformin
The reported incidence of lactic acidosis in patients receiving 
metformin hydrochloride is very low (approximately 
0.03 cases per 1,000 patient-years, with approximately 
0.015 fatal cases per 1,000 patient-years).41 Reported cases 
have occurred primarily in diabetic patients with significant 
renal insufficiency.41 In patients with decreased renal 
function the plasma and blood half-life of metformin is 
prolonged and the renal clearance is decreased in proportion 
to the decrease in creatinine clearance.41 The risk of lactic 
acidosis increases with the degree of renal dysfunction and 
the patient’s age.41
The most common side effects associated with metformin 
therapy largely involve the gastrointestinal system and 
include diarrhea, nausea/vomiting, flatulence, abdominal 
discomfort, indigestion, asthenia, and headache.41
Combination sitagliptin/metformin
No published studies have evaluated the long-term health 
outcomes of combination sitagliptin/metformin for treatment 
of TD2M.
Hypoglycemia was not found to be increased with the 
administration of combination therapy with sitagliptin and 
metformin.25
The package insert for JanumetTM offers additional safety 
information.41
•  There are no adequate and well-controlled studies in 
pregnant women with JanumetTM or its components. 
Therefore its safety in pregnant women is unknown and 
it should only be used during pregnancy only if clearly 
needed. Caution is also advised in women who are 
breastfeeding.41
•  JanumetTM is contraindicated in patients with renal disease 
or renal dysfunction due to the metformin component 
of the drug and the possible development of lactic 
acidosis. JanumetTM should not be initiated, and should be 
discontinued, in men with a serum creatinine 1.5 mg/dL 
and women with a serum creatinine 1.4 mg/dL.41
•  JanumetTM should not be used in patients with chronic 
metabolic acidosis, and should be used cautiously in those 
with a history of diabetic ketoacidosis.41
Sitagliptin/metformin fixed-dose 
combination therapy adherence rates
By taking fixed-dose combination products patients may be 
able to decrease the total number of pills taken during a day 
which potentially improves adherence to therapy.
No studies have been conducted to determine if 
adherence rates favor the fixed-dose combination of 
sitagliptin/metformin tablets or the co-administration of 
the components. However, studies have been conducted 
to determine if adherence rates differed between free-dose 
combination and fixed-dose combination forms of other drugs 
used to treat T2DM.
A retrospective database analysis was conducted by 
Melikian and colleagues42 that reviewed the rate of adherence 
of patients in a managed care organization who were Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 132
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taking glyburide or metformin monotherapy in free-dose 
combination or in fixed-dose combination. Patients were 
divided into two categories; newly treated patients who 
were not treated for diabetes prior to the index date (the 
first prescription fill during the identification period), and 
previously treated patients who were treated for diabetes 
prior to the index date.
The study concluded that for newly-treated patients 
there was no significant differences in adherence over the 
initial six months of pharmacologic therapy between patients 
receiving monotherapy or free-dose combination therapy 
compared with those receiving fixed-dose combination 
therapy.42 Significantly lower adherence rates were observed 
in patients receiving metformin or glyburide monotherapy 
in the pre-index period who had the alternative agent added, 
resulting in combination therapy, at the index date (54%; 
95% CI: 0.52–0.55) compared to those with a switch to 
fixed-dose glyburide/metformin combination therapy at the 
index date.42 There was a significant improvement in adher-
ence rates in patients who had been receiving combination 
therapy in the pre-index period and were switched to fixed-
dose combination therapy at the index date (71% vs 87%; 
p  0.001).42
A study conducted by Blond and colleagues43 found 
similar results. The trial defined adherence as the total 
days’ supply of medication during the study follow-up 
period divided by the length of the follow-up period. It was 
found that patients who were taking the fixed-dose form of 
glyburide/metformin had a drug supply on 84% of the days 
while those who were taking the co-administered components 
had a drug supply on 76% of the days.43
A retrospective database analysis was conducted by 
Vanderpoel and colleagues to asses changes in medica-
tion adherence rates associated with oral hypoglycemic 
agents in subjects switching from either monotherapy 
metformin or rosiglitazone or free-dose administration of 
rosiglitazone and metformin to fixed-dose administration of 
rosiglitazone/metformin. In this study a proxy measurement 
of medication adherence was calculated and higher by 
calculating a medication possession ratio (MPR). Higher 
scores were associated with increased adherence. The study 
concluded fixed-dose combination therapy yielded significant 
improvements in medication adherence rates compared with 
dual therapy regimens44 (Table 3).
Sitagliptin/metformin fixed-dose 
combination efficacy compared 
to efficacy of other fixed-dose 
combination therapies for T2DM
There has only been one study that attempted to compare 
the efficacy of sitagliptin/metformin combination therapy 
with any other drug given in combination with metformin. 
Nauck and colleagues compared sitagliptin/metformin 
with glipizide/metformin combination therapy. This study 
concluded that the addition of 100 mg of sitagliptin to 
ongoing metformin therapy provided similar A1C-lowering 
effects as the addition of glipizide in 5 to 20 mg daily doses 
to ongoing metformin therapy.24 The side effect profile 
favored the sitagliptin/metformin-treated patients over the 
glipizide/metformin-treated patients. More of the glipizide/
metformin-treated patients developed hypoglycemia than the 
sitagliptin/metformin-treated patients (32% vs 5%). Weight 
gain was more of an issue for the glipizide/metformin-treated 
patients than the sitagliptin/metformin-treated patients 
(+1.1 kg with glipizide and -1.5 kg with sitagliptin).24 Cost 
considerations likely would favor treatment with glipizide/
metformin over sitagliptin/metformin since generic forms 
Table 3 endpoints for the treatment arms studied by vanderpoel and colleagues44




Remained on monotherapy 
throughout study
N = 14291 0.90 0.89
Switched to free-dose combination 
therapy after index date
N = 931 0.80 0.67
Switched to a fixed-dose combination 
after index date
N = 349 0.87 0.83
Remained on free-dose combination 
therapy after index date
N = 1,230 0.84 0.83
Switched the fixed-dose combination 
therapy after index date
N = 127 0.79 0.82Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 133
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of metformin and glipizide are available and since generic 
forms of sitagliptin alone or in fixed-dose combination with 
metformin are not.
Place in therapy of fixed-dose 
combination therapy sitagliptin/
metformin
There are now five therapeutic classes of drugs available to be 
used for glycemic control in patients with T2DM; biguanides 
(eg, metformin), insulin secretagogues (eg, sulfonylureas), 
thiazolidinediones, alpha glycosidase inhibitors, and DPP-4 
inhibitors. Five unique drugs are currently available in fixed-
dose combination with metformin; glyburide/metformin, 
glipizide/metformin, rosiglitazone/metformin, pioglitazone/
metformin, and now sitagliptin/metformin. With so many 
choices available, it is important to have an understanding 
of why prescribers might select one drug over the other. 
Prescribing decisions depend on other factors such as 
side-effect profiles, adherence and cost in cases where the 
comparative efficacies of therapies are similar.
The combined formulation of sitagliptin and metformin 
finds a niche with patients currently taking both sitagliptin 
and metformin as separate pills although the dosing flexibility 
of the metformin component diminishes when it is given in 
fixed-dose combination with sitagliptin. Patients who are 
insufficiently controlled on either sitagliptin or metformin 
alone are also candidates for the fixed-dose combination 
therapy.
Conclusion
Patients who are using free-dose combination therapy 
sitagliptin/metformin may benefit from switching to the 
fixed-dose combination therapy.
Other patients who may benefit from fixed-dose combina-
tion therapy with sitagliptin/metformin include those patients 
with hyperglycemia who are uncontrolled on metformin or 
sitagliptin alone, those who tend toward hypoglycemia when 
taking sulfonylureas in combination with metformin, and 
patients with T2DM for whom weight gain is a component 
of their disease and who may be at increased risk for conges-
tive heart failure.
Finally fixed-dose combination therapy with sitagliptin/
metformin may be a reasonable choice for patients who 
are at an increased risk of heart disease. Both pioglitazone 
(Actose®) and rosiglitazone (Avandia®) have FDA “black 
box” warnings that indicate they may cause or worsen 
congestive heart failure and their side effects include fluid 
retention, weight gain, and in rare cases, worsening of heart 
failure and its symptoms.45 Fixed-dose combination therapy 
with sitagliptin/metformin provides an option for patients and 
practitioners who are looking to decrease their pill burden 
and maximize medication adherence.
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